News Room
Media Contacts
1413 K Street NW, 4th Floor
Washington, D.C. 20005
Telephone: (202) 682-2640
Fax: (202) 682-2648
General Inquiries – nwhn@nwhn.org
Media Inquiries – media@nwhn.org
- New Campaign Warns Women of Harm from Drug FDA Approved in AugustNovember 17, 2015FOR IMMEDIATE RELEASE To schedule an interview with Cindy Pearson contact: Sarah Courtney at sarah@wardcirclestrategies.com or 917-913-1994 Feminist Health Advocates Cite Unsafe Sex Drug for Women in Call for Next FDA Commissioner to Resist Political Pressure WASHINGTON, D.C. – As Dr. Robert Califf testifies before the Senate on his nomination for commissioner of the Food and Drug Administration, the National Women’s ...
- Warning of marginal benefits and serious side effects as drug sales beginNovember 12, 2015FOR IMMEDIATE RELEASE To schedule an interview with Cindy Pearson and Susan Wood: Sarah Courtney at sarah@wardcirclestrategies.com or 917-913-1994 “PASS ON THE PINK PILL – OR PASS OUT!” Health Advocates Issue Emergency Alert on Addyi: The New Sex Drug for Women WASHINGTON, DC – The consumer advocacy group National Women’s Health Network (NWHN) today issued its first ever Emergency Alert on Addyi (in four decades ...
- The National Women’s Health Network Continues to Express Deep Concern Over Addyi’s SafetyOctober 16, 2015FOR IMMEDIATE RELEASE Contact: Christina Cherel at ccherel@nwhn.org or (202) 682-2640 Washington, D.C. – Tomorrow, the first FDA-approved drug to treat hypoactive sexual desire disorder (HSDD) in premenopausal women will be available by prescription. The National Women’s Health Network (“the Network”) remains deeply concerned over the unanswered questions regarding Addyi’s interaction with alcohol and the drug’s ability to cause ...
- The National Women’s Health Network expresses profound disappointment with FDA’s decision to approve controversial sex drug.August 19, 2015FOR IMMEDIATE RELEASE Contact: Christina Cherel at ccherel@nwhn.org or (202) 682-2640 WASHINGTON, D.C. – The National Women’s Health Network (the Network) is profoundly disappointed with the U.S. Food and Drug Administration’s (FDA) decision to approve flibanserin, a proposed treatment for female sexual dysfunction, despite inadequate proof of effectiveness and questionable assurances of the drug’s safety. The FDA’s recommendation for ...
- The National Women’s Health Network Celebrates the Introduction of the Equal Access to Abortion Coverage in Health Insurance (EACH) Woman ActJuly 1, 2015FOR IMMEDIATE RELEASE Contact: Media@nwhn.org or Cindy Pearson at 301-938-0356 (Washington, D.C.) The National Women’s Health Network (“the Network”) boldly stands with All* Above All and our pro-choice Congressional champions to restore and sustain abortion coverage for low-income women. We celebrate the introduction of the Equal Access to Abortion Coverage in Health Insurance (EACH) Woman Act as ...
- National Women’s Health Network Urges the FDA to Oppose Twice-Rejected Female Sex DrugJune 3, 2015FOR IMMEDIATE RELEASE Contact: Cindy Pearson at 301-938-0356 or Coco Jervis at 202-407-0788 The National Women’s Health Network (“the Network”) urges the FDA to oppose the approval of Sprout Pharmaceutical’s female sexual dysfunction drug flibanserin. The Network has come to this position after careful consideration of newly disclosed research and thorough evaluation of the drug’s extensive and ...
- National Women’s Health Network Supports Parity in Generic Drug LabelingMarch 27, 2015FOR IMMEDIATE RELEASE Contact: Coco Jervis 202.407.0788 Advocates from the National Women’s Health Network are out in force this week at the FDA and on the Hill urging FDA officials to approve of a proposed Generic Drug Labeling Rule. This rule would give women access to better and more accurate information about the risks and benefits of ...